Kodiak Sciences Inc.
2631 Hanover Street
74 articles with Kodiak Sciences Inc.
Kodiak Sciences Announces Completion of 12-Week Phase 1a Study of KSI-301 in Patients with Diabetic Macular Edema Demonstrating Safety and Durability of Responses Following Single Dose of Intravitreal Anti-VEGF Antibody Biopolymer Conjugate
Rapid high-magnitude and durable treatment responses were seen at all dose levels tested in a heavily pre-treated Phase 1 patient population.
Kodiak Sciences Inc.today reported business highlights and financial results for the third quarter ended September 30, 2018.
A summary of IPOs from companies in the biotech and pharma world since Oct. 1, 2018.
10/31/2018October was a busy month as multiple biopharma companies made their debut as publicly traded entities and even more companies filed their intentions to go public with an initial public offering. BioSpace takes a look back at some of the key IPOs of the month.
Kodiak Sciences Inc. today announced the closing on October 9, 2018 of its initial public offering of 9,000,000 shares of common stock at a price to the public of $10.00 per share.
Kodiak Sciences Inc. today announced the pricing of its initial public offering of 9,000,000 shares of its common stock at a price to the public of $10.00 per share.
Emeryville, Calif.-based Gritstone Oncology hits the ground running today on the Nasdaq Exchange after raising $100 million in an initial public offering.
Kodiak Sciences Inc. today announced that it has launched an initial public offering of 9,000,000 shares of its common stock at an anticipated initial offering price between $13.00 and $15.00 per share
According to BioPharm Catalyst there were, or soon will be, 58 biopharma IPOs in 2018. And the trend doesn’t appear to be slowing. Here’s a look at five upcoming biotech IPOs.
Kodiak Sciences Inc. today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to a proposed initial public offering of its common stock.
Kodiak Sciences Announces Completion of Enrollment in the Company's Phase 1 Safety and Tolerability Study in Patients with Retinal Disease
Kodiak Sciences Inc. today announced that enrollment of patients in the company's phase 1 safety and tolerability study has been completed. First patient in was dosed on July 12, 2018 and last patient in was dosed on August 13, 2018.
Kodiak Sciences Appoints Bassil I. Dahiyat, Ph.D. Robert A. Profusek, J.D. and Richard S. Levy, M.D. to its Board of Directors
Kodiak Sciences Inc. announced the appointments of Bassil I. Dahiyat, Ph.D., Robert A. Profusek, J.D., and Richard S. Levy, M.D. to its Board of Directors.
Kodiak Sciences Inc. announced that presentations on its research will be made at the Association for Research in Vision and Ophthalmology (ARVO) 2018 Annual Meeting, being held from April 29 - May 3 in Honolulu, Hawaii.
Kodiak Sciences Inc. announced the completion of a $33 million mezzanine private financing of convertible notes.